Journal
ADVANCED SCIENCE
Volume 10, Issue 2, Pages -Publisher
WILEY
DOI: 10.1002/advs.202204598
Keywords
antibody; cancer; cytotoxic T lymphocyte; glyconanoparticle; SARS-CoV-2
Ask authors/readers for more resources
Researchers have developed functionalized nanoparticles as a universal vaccine design platform for major diseases such as cancer and COVID-19. The nanoparticles induce potent immune responses and provide effective protection against tumors and the SARS-CoV-2 virus.
Major diseases, such as cancer and COVID-19, are frightening global health problems, and sustained action is necessary to develop vaccines. Here, for the first time, ethoxy acetalated dextran nanoparticles (Ace-Dex-NPs) are functionalized with 9-N-(4H-thieno[3,2-c]chromene-2-carbamoyl)-Sia alpha 2-3Gal beta 1-4GlcNAc ((TCC)Sia-LacNAc) targeting macrophages as a universal vaccine design platform. First, azide-containing oxidized Ace-Dex-NPs are synthesized. After the NPs are conjugated with ovalbumin (OVA) and resiquimod (Rd), they are coupled to (TCC)Sia-LacNAc-DBCO to produce (TCC)Sia-Ace-Dex-OVA-Rd, which induce a potent, long-lasting OVA-specific cytotoxic T-lymphocyte (CTL) response and high anti-OVA IgG, providing mice with superior protection against tumors. Next, this strategy is exploited to develop vaccines against infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is the main target for neutralizing antibodies. The (TCC)Sia-Ace-Dex platform is preferentially used for designing an RBD-based vaccine. Strikingly, the synthetic (TCC)Sia-Ace-Dex-RBD-Rd elicited potent RBD-neutralizing antibodies against live SARS-CoV-2 infected Vero E6 cells. To develop a universal SARS-CoV-2 vaccine, the (TCC)Sia-Ace-Dex-N-Rd vaccine carrying SARS-CoV-2 nucleocapsid protein (N) is also prepared, which is highly conserved among SARS-CoV-2 and its variants of concern (VOCs), including Omicron (BA.1 to BA.5); this vaccine can trigger strong N-specific CTL responses against target cells infected with SARS-CoV-2 and its VOCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available